{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:50:16Z","timestamp":1790769016910,"version":"4.1.0"},"reference-count":5,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>It has been suggested that treatment with ethyl\u2010eicosapentaenoic acid (EPA) may improve motor function in patients with Huntington's disease (HD) with cytosine\u2010adenine\u2010guanine repeat numbers of &lt;45.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This multicenter, randomized, double\u2010blind, placebo\u2010controlled 6\u2010month trial compared the effects of ethyl\u2010EPA versus placebo on 290 subjects with mild\u2010to\u2010moderate HD. The primary endpoint was the change from baseline to 6 months in the Total Motor Score 4 (TMS\u20104) component of the Unified Huntington's Disease Rating Scale (UHDRS). Secondary endpoints included change from baseline in UHDRS subscores and Clinical Global Impression (CGI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No significant differences in TMS\u20104 scores were noted between treatment groups. Similarly, there were no significant differences between groups on any of the UHDRS subscores or CGI scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Ethyl\u2010EPA was not beneficial in patients with HD during 6 months of placebo\u2010controlled evaluation. \u00a9 2015 International Parkinson and Movement Disorder Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/mds.26308","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T16:09:09Z","timestamp":1436890149000},"page":"1426-1429","source":"Crossref","is-referenced-by-count":38,"title":["Ethyl\u2010eicosapentaenoic acid treatment in Huntington's disease: A placebo\u2010controlled clinical trial"],"prefix":"10.1002","volume":"30","author":[{"given":"Joaquim J.","family":"Ferreira","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon  Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Rosser","sequence":"additional","affiliation":[{"name":"Cardiff Schools of Medicine and Biosciences Cardiff University  United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Craufurd","sequence":"additional","affiliation":[{"name":"University of Manchester, Manchester Academic Health Sciences Center and Central Manchester University Hospitals NHS Foundation Trust Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Squitieri","sequence":"additional","affiliation":[{"name":"IRCSS Neuromed Pozzilli Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Mallard","sequence":"additional","affiliation":[{"name":"Amarin Pharma Inc. Bedminster New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Landwehrmeyer","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinik Ulm Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,14]]},"reference":[{"issue":"3","key":"e_1_2_9_2_1","first-page":"CD006455","article-title":"Therapeutic interventions for disease progression in Huntington's disease","author":"Mestre T","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2006.10.020"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000169025.09670.6d"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.12.1582"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120214"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26308","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26308","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:09:12Z","timestamp":1760969352000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.26308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,14]]},"references-count":5,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1002\/mds.26308"],"URL":"https:\/\/doi.org\/10.1002\/mds.26308","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,14]]}}}